Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial
Hahn J, Cook NR, Alexander EK, Friedman S, Walter J, Bubes V, Kotler G, Lee IM, Manson JE, Costenbader KH
BMJ (Clinical research ed.) · 282 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Institutes of Health
- Gobierno
- National Cancer Institute
- Gobierno
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- Gobierno
- National Center for Complementary and Integrative Health
- Gobierno
- NCI NIH HHS
- Gobierno
- NCCIH NIH HHS
- Gobierno
- NIAMS NIH HHS
- Subvenciones
- National Cancer Institute (R01 CA138962); National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR059086); National Center for Complementary and Integrative Health (R01 AT011729)
Según 7 financiadores declarados y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2022-01-26 · BMJ · vol. 376 · pág. e066452
- Citado
- 418 citas · más que el 100% de estudios similares · 52.4× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 40 trabajos
- Acceso
- Acceso abierto (revista híbrida) · CC-BY-NC
- Áreas de investigación
- Vitamin D Research Studies · Fatty Acid Research and Health · Spondyloarthritis Studies and Treatments
- Palabras clave
- Medicine, Hazard ratio, Internal medicine, Rheumatoid arthritis, Vitamin D and neurology, Clinical endpoint, Placebo, Randomized controlled trial, Gastroenterology, Confidence interval, Pathology
- MeSH
- humans, autoimmune diseases, cholecalciferol, fatty acids, omega-3, treatment outcome, incidence, follow-up studies, double-blind method, dietary supplements, aged, middle aged, female, male
10 autores
- Jill Hahn🇺🇸Brigham and Women's Hospital; Harvard University
- Nancy R. Cook🇺🇸Brigham and Women's Hospital; Harvard University
- Erik Karl Alexander🇺🇸Brigham and Women's Hospital; Harvard University
- Sonia Friedman🇺🇸Brigham and Women's Hospital
- Joseph N. Walter🇺🇸Brigham and Women's Hospital; Harvard University
- Vadim Y. Bubes🇺🇸Brigham and Women's Hospital; Harvard University
- Gregory Kotler🇺🇸Brigham and Women's Hospital; Harvard University
- I‐Min Lee🇺🇸Brigham and Women's Hospital; Harvard University
- JoAnn E. Manson🇺🇸Brigham and Women's Hospital; Harvard University
- Karen H. Costenbader🇺🇸 · autor de correspondenciaBrigham and Women's Hospital; Harvard University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Objective
To investigate whether vitamin D and marine derived long chain omega 3 fatty acids reduce autoimmune disease risk.
Design
Vitamin D and omega 3 trial (VITAL), a nationwide, randomized, double blind, placebo controlled trial with a two-by-two factorial design.
Setting
Nationwide in the United States.
Participants
25 871 participants, consisting of 12 786 men ≥50 years and 13 085 women ≥55 years at enrollment.
Interventions
Vitamin D (2000 IU/day) or matched placebo, and omega 3 fatty acids (1000 mg/day) or matched placebo. Participants self-reported all incident autoimmune diseases from baseline to a median of 5.3 years of follow-up; these diseases were confirmed by extensive medical record review. Cox proportional hazard models were used to test the effects of vitamin D and omega 3 fatty acids on autoimmune disease incidence.
Main outcome measures
The primary endpoint was all incident autoimmune diseases confirmed by medical record review: rheumatoid arthritis, polymyalgia rheumatica, autoimmune thyroid disease, psoriasis, and all others.
Results
25 871 participants were enrolled and followed for a median of 5.3 years. 18 046 self-identified as non-Hispanic white, 5106 as black, and 2152 as other racial and ethnic groups. The mean age was 67.1 years. For the vitamin D arm, 123 participants in the treatment group and 155 in the placebo group had a confirmed autoimmune disease (hazard ratio 0.78, 95% confidence interval 0.61 to 0.99, P=0.05). In the omega 3 fatty acids arm, 130 participants in the treatment group and 148 in the placebo group had a confirmed autoimmune disease (0.85, 0.67 to 1.08, P=0.19). Compared with the reference arm (vitamin D placebo and omega 3 fatty acid placebo; 88 with confirmed autoimmune disease), 63 participants who received vitamin D and omega 3 fatty acids (0.69, 0.49 to 0.96), 60 who received only vitamin D (0.68, 0.48 to 0.94), and 67 who received only omega 3 fatty acids (0.74, 0.54 to 1.03) had confirmed autoimmune disease.
Conclusions
Vitamin D supplementation for five years, with or without omega 3 fatty acids, reduced autoimmune disease by 22%, while omega 3 fatty acid supplementation with or without vitamin D reduced the autoimmune disease rate by 15% (not statistically significant). Both treatment arms showed larger effects than the reference arm (vitamin D placebo and omega 3 fatty acid placebo).
Study registration
ClinicalTrials.gov NCT01351805 and NCT01169259.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.